Following on the announcement of Phase 2 advancement of their first NK-cell-based immunotherapy, KI startup company Dragonfly Therapeutics has dosed their first patient in the Phase 1/2 trial of another drug, DF9001. The sixth in an exciting pipeline of Dragonfly drugs to enter clinical trials, DF9001 is being tested alone and in combination with PD-1 checkpoint inhibitors in patients with locally advanced or metastatic solid tumors.